NICE recommends Ilumetri to treat plaque psoriasis
Almirall, S.A. announced that NICE (National Institute for Health and Care Excellence) has provisionally recommended approval of Ilumetri (tildrakizumab) (Ilumya in the US), a humanized, high-affinity IL-23p19 monoclonal antibody, for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
Following a single health technology assessment submission to NICE in August 2018 and the subsequent questions for clarification and appraisal committee meetings, NICE completed their assessment of tildrakizumab and has now issued a Final Appraisal Determination (FAD) provisionally recommending tildrakizumab as a cost effective treatment option for the NHS for the patients specified in the FAD. Final NICE approval is expected in April 2019.
Learn more about psoriasis in our Psoriasis Learning Zone.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.